Arzerra, INN-ofatumumab
EMA: Ofatumumab bei schubförmiger Multipler Sklerose zugelassen
PDF) The European Medicines Agency Review of Ofatumumab (Arzerra(R)) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines
Genmab Announces European Regulatory Submission for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed
Pan-Canadian Oncology Drug Review Final Clinical Guidance Report Ofatumumab (Arzerra) for Chronic Lymphocytic Leukemia
Arzerra, INN-ofatumumab
Arzerra outperformed by business partner — MedWatch
Arzerra til eksamen hos EMA
Genmab meddeler, at der er indsendt registreringsansøgning i Europa for ofatumumab i kombination med fludarabin og cyclofosfami
Ofatumumab
EMA, FDA both accept filing of Novartis' ofatumumab - PharmaTimes
Arzerra II-21 DHPC
Arzerra, INN-ofatumumab
Arzerra - Public statement
Novartis announces FDA and EMA filing acceptance of ofatumumab (OMB157), a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS) - LifeProNow LifeProNow
Arzerra (Ofatumumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL) - Clinical Trials Arena
EMA and Progressive Multifocal Leukoencephalopathy. - PDF Free Download
Arzerra II-27 Final DHPC and communication plan
Clinical Trials in Rare Diseases Brendan M. Buckley MD DPhil FRCPI College of Medicine and Health University College Cork Insights into Successful Research. - ppt download
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Arzerra, INN-ofatumumab
Australian Public Assessment Report for Ofatumumab
![PDF] Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5dfbcbb78c538de4ca5b73ea323128892c2a90e4/3-Table2-1.png "PDF] Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). | Semantic Scholar")